Clinical Trials Browser

Recruiting × NIH × 90 days × Clear all

NCT00026884 2026-03-19

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

Urinary Bladder Neoplasms, Kidney Neoplasms, Neoplasms, Neoplastic Syndromes, Hereditary

NCT01143480 2026-03-19

Study of the Effect of Innate on the Inflammatory Response to Endotoxin

Asthma, Insulin Resistance, Neoplasms, Metabolic Syndrome, Atherosclerosis

NCT03191149 2026-03-19

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04071236 2026-03-19

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

Phase 1/2 Recruiting

Lymphatic Metastasis, Prostatic Neoplasms

NCT04269902 2026-03-19

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Phase 3 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04550494 2026-03-19

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Phase 2 Recruiting

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT04633239 2026-03-19

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

Phase 1 Recruiting

Recurrent Ovarian High Grade Serous Adenocarcinoma

NCT05019716 2026-03-19

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

Phase 1/2 Recruiting

Advanced NUT Carcinoma

NCT05256225 2026-03-19

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Phase 3 Recruiting

Neoplasms, Endometrial Neoplasms

NCT05327010 2026-03-19

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

Phase 2 Recruiting

Neoplasm Metastasis

NCT05333458 2026-03-19

Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial

Phase 2 Recruiting

Sarcoma, Alveolar Soft Part

NCT05621291 2026-03-19

A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...

Phase NA Recruiting

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05630794 2026-03-19

Testing for Safety and Colorectal Cancer Preventive Effects of ONC201

Phase 1 Recruiting

Gastrointestinal

Adenomatous Polyposis Coli, Colorectal Neoplasms

NCT05638295 2026-03-19

Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)

Phase 2 Recruiting

Neoplasm Metastasis

NCT05675410 2026-03-19

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Phase 3 Recruiting

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

NCT05685602 2026-03-19

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

Phase 1 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05687110 2026-03-19

Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes

Phase 1 Recruiting

Neoplasm Metastasis

NCT05687123 2026-03-19

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

Phase 1 Recruiting

Gastrointestinal

Adenoma, Islet Cell, Pancreatic Neoplasms

NCT05691478 2026-03-19

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

Phase 2/3 Recruiting

Osteosarcoma

NCT05691504 2026-03-19

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Phase 1 Recruiting

GynecologicSarcoma

Carcinosarcoma, Fallopian Tube Neoplasms, Endometrial Neoplasms

NCT05691517 2026-03-19

Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers

Phase 1 Recruiting

Neoplasm Metastasis

NCT05773274 2026-03-19

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

Phase 2 Recruiting

Metastatic Digestive System Neuroendocrine Tumor G1

NCT05803382 2026-03-19

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

Phase 1 Recruiting

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT05859334 2026-03-19

Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment

Phase 2 Recruiting

Glioma

NCT05896839 2026-03-19

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

Phase 1/2 Recruiting

Carcinoma, Basal Cell, Melanoma, Carcinoma, Merkel Cell

NCT05950464 2026-03-19

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Phase 1 Recruiting

Endometrial Neoplasms

NCT06064097 2026-03-19

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT06096870 2026-03-19

Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy

Phase 2 Recruiting

Prostatic Neoplasms

NCT06184750 2026-03-19

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

Phase 2 Recruiting

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT06311227 2026-03-19

Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Hairy Cell

NCT06498648 2026-03-19

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

Phase 1/2 Recruiting

Leiomyosarcoma, Liposarcoma, Sarcoma

NCT06514261 2026-03-19

Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML

Phase 1 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06568172 2026-03-19

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

Phase 3 Recruiting

DermatologicHead & NeckSarcoma

Eyelid Squamous Cell Carcinoma

NCT06696768 2026-03-19

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

Phase 1 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06876142 2026-03-19

Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

Phase 1/2 Recruiting

Multiple Myeloma

NCT06980038 2026-03-19

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms

NCT07003295 2026-03-19

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

Phase 2 Recruiting

Lymphoma, Mantle-Cell

NCT07012031 2026-03-19

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07061964 2026-03-19

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT07308886 2026-03-19

Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)

Phase 2 Recruiting

LymphoidSarcoma

Lymphoproliferative Disorders, Sarcoma, Kaposi

NCT00804154 2026-03-18

Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

Phase 1 Recruiting

Cancer Pain, Pain, Intractable

NCT03375307 2026-03-18

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT03816345 2026-03-18

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

Phase 1 Recruiting

Other hematologic neoplasm

Arthritis, Rheumatoid, Autoimmune Diseases, Colitis, Ulcerative, Crohn Disease, Dermatomyositis, Lupus Erythematosus, Systemic, Multiple Sclerosis, Psoriasis, Scleroderma, Systemic, Sjogren's Syndrome, Inflammatory Bowel Diseases, Arthritis, Psoriatic, Hematologic Neoplasms

NCT03866382 2026-03-18

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Phase 2 Recruiting

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT03907475 2026-03-18

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

Phase 2 Recruiting

Neoplasm Metastasis

NCT04172532 2026-03-18

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

Phase 1/2 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT04314401 2026-03-18

National Cancer Institute "Cancer Moonshot Biobank"

BreastDermatologicGastrointestinalGenitourinaryGynecologicOther hematologic neoplasmPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04402788 2026-03-18

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

Phase 2/3 Recruiting

Extensive Stage Lung Small Cell Carcinoma

NCT04569591 2026-03-18

DDAVP for Pituitary Adenoma

Phase NA Recruiting

Pituitary Neoplasms, Pituitary ACTH Hypersecretion

NCT04628767 2026-03-18

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Phase 2/3 Recruiting

Renal Pelvis and Ureter Urothelial Carcinoma